Company intelligence / Profile preview

Boundless Bio

San Diego, California, United Statesboundlessbio.com ↗

Ownership: Public · BOLD
Employees: ~72
Development stage: Phase 1

Overview

Currently conducting Phase 1/2 POTENTIATE trial for BBI-355 (CHK1 inhibitor) in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025. Recently discontinued development of BBI-825 due to pharmacokinetic concerns.

Therapeutic areas: Oncology
Modalities: Small moleculesoral inhibitorsoral degraders
Industry: Biotech

Drug pipeline

5 assets

BBI-825

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $64.1M
Total revenue: $0
Enterprise value: $-8.6M

Beyond the preview

Go deeper on Boundless Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boundless Bio.

Explore the full profile